{"doc_id": "si-2020-0098-reg-1", "parent_doc_id": "si-2020-0098", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) Regulations 2020. \n\n(2) The Principal Regulations, the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2005 (S.I. No. 510 of 2005), the \nRegulations of 2007, Part 4 of the Medicinal Products (Control of Placing on \nthe Market) Regulations 2007 (S.I. No. 540 of 2007), the Medicinal Products \n(Prescription and Control of Supply) (Amendment) Regulations 2008 (S.I. No. \n512 of 2008), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) Regulations 2009 (S.I. No. 442 of 2009), the Medicinal Products \n(Prescription and Control of Supply) (Amendment) Regulations 2011 (S.I. No. \n525 of 2011), the Medicinal Products (Prescription and Control of Supply) \n(Amendment) Regulations 2014 (S.I. No. 300 of 2014), the Regulations of \n2014, the Regulations of 2015, the Regulations (No. 2) of 2015, the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) Regulations 2018 \n(S.I. No. 530 of 2018) and these Regulations may be cited together as the \nMedicinal Products (Prescription and Control of Supply) Regulations 2003 to", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) regulation 2020 (2) principal regulation medicinal product (prescription control supply) (amendment) regulation 2005 (s.i no 510 2005) regulation 2007 part 4 medicinal product (control placing market) regulation 2007 (s.i no 540 2007) medicinal product (prescription control supply) (amendment) regulation 2008 (s.i no 512 2008) medicinal product (prescription control supply) (amendment) regulation 2009 (s.i no 442 2009) medicinal product (prescription control supply) (amendment) regulation 2011 (s.i no 525 2011) medicinal product (prescription control supply) (amendment) regulation 2014 (s.i no 300 2014) regulation 2014 regulation 2015 regulation (no 2) 2015 medicinal product (prescription control supply) (amendment) regulation 2018 (s.i no 530 2018) regulation may cited together medicinal product (prescription control supply) regulation 2003", "start_char": 619, "end_char": 1820, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-2020", "parent_doc_id": "si-2020-0098", "section_id": "reg-2020", "section_label": "Regulation 2020.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": null, "text_raw": "2020.", "text_norm": "2020", "start_char": 1820, "end_char": 1828, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-2", "parent_doc_id": "si-2020-0098", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription \nand Control of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2007” means the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2007 (S.I. No. 201 of \n2007); \n\n“Regulations of 2014” means the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 2) Regulations 2014 (S.I. No. \n504 of 2014); \n\n“Regulations of 2015” means the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2015 (S.I. No. 87 of \n2015); \n\n“Regulations (No. 2) of 2015” means \nthe Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 2) Regulations \n2015 (S.I. No. 449 of 2015). \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 10th April, 2020. \n\n \n \n \n \n \n \n \n\f[98] 3", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2007 mean medicinal product (prescription control supply) (amendment) regulation 2007 (s.i no 201 2007) regulation 2014 mean medicinal product (prescription control supply) (amendment) (no 2) regulation 2014 (s.i no 504 2014) regulation 2015 mean medicinal product (prescription control supply) (amendment) regulation 2015 (s.i no 87 2015) regulation (no 2) 2015 mean medicinal product (prescription control supply) (amendment) (no 2) regulation 2015 (s.i no 449 2015) notice making statutory instrument published iris oifigiuil 10th april 2020 98 3", "start_char": 1828, "end_char": 2727, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-3", "parent_doc_id": "si-2020-0098", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "3. Regulation 4(1) (as amended by Regulation 3 of the Regulations (No.", "text_raw": "3. Regulation 4(1) (as amended by Regulation 3 of the Regulations (No. \n\n2) of 2015) of the Principal Regulations is amended— \n\n(a) by inserting after the definition of “controlled drug” the \n\nfollowing definition: \n\n“‘Covid-19 emergency’ means the situation resulting from the \nspread in the State of the disease caused by infection with the \nvirus SARS-CoV-2, being a disease specified as an infectious \ndisease in accordance with Regulation 6 of, and the Schedule to, \nthe Infectious Diseases Regulations 1981 (S.I. No. 390 of 1981), \nor any variant of the disease so specified as an infectious disease \nin those Regulations;”, \n\n(b) by inserting after the definition of “the Minister” the following \n\ndefinition: \n\n“‘national electronic prescription transfer system’ means a \nsystem providing for the transfer of prescriptions, in permanent \nand unalterable form, by electronic means approved, on behalf \nof the Health Service Executive, by the head of the Primary \nCare Reimbursement Service (PCRS) and the Chief Information \nOfficer;”, and \n\n(c) \n\nby inserting after the definition of “product authorisation” the \nfollowing definition: \n\n“‘professional registration number’ means— \n\n(a) \n\n(b) \n\n(c) \n\nin the case of a registered medical practitioner, the number \nattached to the medical practitioner’s registration in \naccordance with section 43(5) of the Medical Practitioners \nAct 2007 (No. 25 of 2007), \n\nin the case of a registered nurse, the number attached to \nthe nurse’s registration in accordance with section 46(7) of \nthe Nurses and Midwives Act 2011 (No. 41 of 2011), or \n\nin the case of a registered dentist, the number assigned by \nthe Dental Council to the dentist’s registration in the \nRegister of Dentists in accordance with section 26 of the \nDentists Act 1985;”.", "text_norm": "3 regulation 4(1) (as amended regulation 3 regulation (no 2) 2015) principal regulation amended-- (a) inserting definition controlled drug following definition covid-19 emergency mean situation resulting spread state disease caused infection virus sars-cov-2 disease specified infectious disease accordance regulation 6 schedule infectious disease regulation 1981 (s.i no 390 1981) variant disease specified infectious disease regulation (b) inserting definition minister following definition national electronic prescription transfer system mean system providing transfer prescription permanent unalterable form electronic mean approved behalf health service executive head primary care reimbursement service (pcrs) chief information officer (c) inserting definition product authorisation following definition professional registration number means-- (a) (b) (c) case registered medical practitioner number attached medical practitioner registration accordance section 43(5) medical practitioner act 2007 (no 25 2007) case registered nurse number attached nurse registration accordance section 46(7) nurse midwife act 2011 (no 41 2011) case registered dentist number assigned dental council dentist registration register dentist accordance section 26 dentist act 1985", "start_char": 2727, "end_char": 4518, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-4", "parent_doc_id": "si-2020-0098", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "4. Regulation 7 (as amended by Regulation 4 of the Regulations of 2014)", "text_raw": "4. Regulation 7 (as amended by Regulation 4 of the Regulations of 2014) \n\nof the Principal Regulations is amended— \n\n(a) \n\nin paragraph (1), by substituting for subparagraph (a) the \nfollowing: \n\n“(a) be in— \n\n(i) \n\nink and be signed by the person issuing it with his or \nher usual signature and be dated by him or her, or \n\n(ii) electronic \n\nform, \n\nthe national \nelectronic prescription transfer system and clearly \nindicate the date of issuance and, without prejudice \n\ntransmitted by \n\n \n \n\f4 [98] \n\nto subparagraph (c)(ii), the professional registration \nnumber of the person issuing it, and must be \ntraceable electronically back to him or her;”, \n\n(b) by inserting after paragraph (2) the following paragraph: \n\n“(2A) Notwithstanding the provisions of paragraph (2), in the \ncircumstances arising from the Covid-19 emergency, the \nfollowing provisions shall apply to the dispensing of a \nprescription for the supply of a medicinal product: \n\n(a) where neither the number of occasions on which, nor the \nintervals at which, a medicinal product, which is or which \ncontains a substance specified in Part A of the First \nSchedule and which is not listed in Schedule 2 or 3, or \nPart 1 of Schedule 4, of the Misuse of Drugs Regulations \n2017 (S.I. No. 173 of 2017), may be supplied are specified \nin a prescription, the prescription may be dispensed on one \nadditional occasion, where, in the opinion of the person \ndispensing the prescription, it is— \n\n(i) \n\nappropriate and necessary \nthe continued \ntreatment of the person for a further supply to be \nmade, and \n\nfor \n\n(ii) unreasonable at \n\nthe \n\ntime of supply, \n\nthe \ncircumstances arising from the Covid-19 emergency, \nto require the person to obtain a new prescription for \nthat medicinal product; \n\nin \n\n(b) where neither the number of occasions on which, nor the \nintervals at which, a medicinal product, which is or which \ncontains a substance specified in Part B of the First \nSchedule but which does not contain a substance specified \nin Part A of the said Schedule, may be supplied are \nspecified in a prescription, the prescription may be \ndispensed on such number of occasions within the period \nof nine months after the date thereon as, in the opinion of \nthe person dispensing the prescription, is appropriate and \nnecessary for the continued treatment of the person; \n\n(c) \n\nin the case of a health prescription for a medicinal product, \nwhich is or which contains a substance specified in Part A \nof the First Schedule and which is not listed in Schedule 2 \nor 3, or Part 1 of Schedule 4, of the Misuse of Drugs \nRegulations 2017, and which is not ordinarily endorsed to \nbe repeated, where, in the opinion of the person dispensing \nthe prescription, it is appropriate and necessary for the \ncontinued treatment of the person for further supplies to be \nmade, the prescription may be dispensed on not more than \nfour occasions; \n\n(d) where the intervals at which a medicinal product, which is \nor which contains a substance specified in Part A of the \nFirst Schedule, may be supplied, are specified in a \n\n \n\f[98] 5 \n\nprescription but the number of occasions on which it may \nbe supplied are not so specified, the prescription may be \ndispensed on not more than four occasions; \n\n(e) where the intervals at which a medicinal product, which is \nor which contains a substance specified in Part B of the \nFirst Schedule but which does not contain a substance \nspecified in Part A of the said Schedule, may be supplied \nare specified in a prescription, the prescription may be \ndispensed at those intervals within the period of nine \nmonths after the date thereon; \n\n(f) where the number of occasions on which a medicinal \nproduct, which is or which contains a substance specified \nin either Part A or Part B of the First Schedule, may be \nsupplied is specified in a prescription but the intervals at \nwhich it may be supplied are not so specified, the \nprescription may be dispensed at such intervals as the \nperson dispensing the prescription considers appropriate \nhaving regard to the specified rate of dosage; \n\n(g) where the number of occasions, as specified on the \nprescription, on which a medicinal product, which is or \nwhich contains a substance specified in either Part A or \nPart B of the First Schedule, may be supplied has been \nreached, the prescription may be dispensed on three \nfurther occasions where, in the opinion of the person \ndispensing the prescription, it is appropriate and necessary \nfor the continued treatment of the person for further \nsupplies to be made; \n\n(h) where the dispensing of a prescription has been completed \nbefore the commencement of the Medicinal Products \n(Prescription and Control of Supply) (Amendment) \nRegulations 2020 (S.I. No. 98 of 2020), and \nthe \nin accordance with \nprescription has been endorsed \nparagraph (2)(f), additional supplies may be made against \nsuch prescription, \nthe provisions of \nsubparagraphs (a) to (g); \n\nsubject \n\nto \n\n(i) where \n\nthe original prescription \n\nis not available, a \nmedicinal product may nonetheless be supplied \nin \naccordance with this paragraph and paragraph (2)(f) and \n(g) shall not apply, provided the person dispensing the \nprescription makes a record of the reasons for the making \nof the supply.”, and \n\n(c) \n\nin paragraph (5)— \n\n(i) \n\nin subparagraph (a), by substituting “nine” for “six”, and \n\n(ii) by substituting for subparagraph (b) the following: \n\n“(b) except in the case of— \n\n \n\f6 [98] \n\n(i) a health prescription \n\nis a repeatable \nprescription upon which a second or subsequent \nsupply of a medicinal product is being made, \n\nthat \n\n(ii) a prescription transmitted in electronic form via \ntransfer \n\nthe national electronic prescription \nsystem, or \n\n(iii) a prescription dispensed pursuant to paragraph \n\n(2A), \n\nbe an original as issued by the registered medical \npractitioner, registered dentist or registered nurse;”.", "text_norm": "4 regulation 7 (as amended regulation 4 regulation 2014) principal regulation amended-- (a) paragraph (1) substituting subparagraph (a) following (a) in-- (i) ink signed person issuing usual signature dated (ii) electronic form national electronic prescription transfer system clearly indicate date issuance without prejudice transmitted 4 98 subparagraph (c)(ii) professional registration number person issuing must traceable electronically back (b) inserting paragraph (2) following paragraph (2a) notwithstanding provision paragraph (2) circumstance arising covid-19 emergency following provision shall apply dispensing prescription supply medicinal product (a) neither number occasion interval medicinal product contains substance specified part first schedule listed schedule 2 3 part 1 schedule 4 misuse drug regulation 2017 (s.i no 173 2017) may supplied specified prescription prescription may dispensed one additional occasion opinion person dispensing prescription is-- (i) appropriate necessary continued treatment person supply made (ii) unreasonable time supply circumstance arising covid-19 emergency require person obtain new prescription medicinal product (b) neither number occasion interval medicinal product contains substance specified part b first schedule contain substance specified part said schedule may supplied specified prescription prescription may dispensed number occasion within period nine month date thereon opinion person dispensing prescription appropriate necessary continued treatment person (c) case health prescription medicinal product contains substance specified part first schedule listed schedule 2 3 part 1 schedule 4 misuse drug regulation 2017 ordinarily endorsed repeated opinion person dispensing prescription appropriate necessary continued treatment person supply made prescription may dispensed four occasion (d) interval medicinal product contains substance specified part first schedule may supplied specified 98 5 prescription number occasion may supplied specified prescription may dispensed four occasion (e) interval medicinal product contains substance specified part b first schedule contain substance specified part said schedule may supplied specified prescription prescription may dispensed interval within period nine month date thereon (f) number occasion medicinal product contains substance specified either part part b first schedule may supplied specified prescription interval may supplied specified prescription may dispensed interval person dispensing prescription considers appropriate regard specified rate dosage (g) number occasion specified prescription medicinal product contains substance specified either part part b first schedule may supplied reached prescription may dispensed three occasion opinion person dispensing prescription appropriate necessary continued treatment person supply made (h) dispensing prescription completed commencement medicinal product (prescription control supply) (amendment) regulation 2020 (s.i no 98 2020) accordance prescription endorsed paragraph (2)(f) additional supply may made prescription provision subparagraphs (a) (g) subject (i) original prescription available medicinal product may nonetheless supplied accordance paragraph paragraph (2)(f) (g) shall apply provided person dispensing prescription make record reason making supply (c) paragraph (5)-- (i) subparagraph (a) substituting nine six (ii) substituting subparagraph (b) following (b) except case of-- 6 98 (i) health prescription repeatable prescription upon second subsequent supply medicinal product made (ii) prescription transmitted electronic form via transfer national electronic prescription system (iii) prescription dispensed pursuant paragraph (2a) original issued registered medical practitioner registered dentist registered nurse", "start_char": 4518, "end_char": 10426, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-5", "parent_doc_id": "si-2020-0098", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "5. Regulation 8 (as amended by Regulation 6 of the Regulations of 2007)", "text_raw": "5. Regulation 8 (as amended by Regulation 6 of the Regulations of 2007) \n\nof the Principal Regulations is amended— \n\n(a) \n\nin paragraph (2)(b), by substituting “10 days’” for “5 days’”, \nand \n\n(b) by inserting after paragraph (3) the following paragraphs: \n\nin \n\nthe circumstances arising from \n\n“(4) Notwithstanding the provisions of paragraphs (1)(d) and \n(2)(c), \nthe Covid-19 \nemergency, an authorised person who supplies a controlled drug \nspecified in Schedule 2, 3 or 4 to the Misuse of Drugs \nin accordance with a \nRegulations 2017 otherwise \nprescription is not guilty of an offence where, in the opinion of \nthe authorised person, it is— \n\nthan \n\n(a) unreasonable at the time of supply, in the circumstances \narising from the Covid-19 emergency, for the person to \nobtain a new prescription for that medicinal product, and \n\n(b) \n\nsafe, appropriate and necessary for the continued treatment \nof the person for an emergency supply to be made, \n\nand no greater quantity of the product than will provide 5 days’ \ntreatment is supplied. \n\n(5) Notwithstanding the provisions of paragraphs (1)(d), \n(2)(c) and (4), in the circumstances arising from the Covid-19 \nemergency, the conditions specified in paragraph (1)(d) and \n(2)(c) shall not apply where the product consists of or contains \nmidazolam, clobazam or clonazepam (but no other substance \nspecified in the Fourth Schedule or in Schedule 1, 2, 3 or 4 to \nthe Misuse of Drugs Regulations 2017 or any amendment \nthereof) and is supplied for the treatment of epilepsy.”.", "text_norm": "5 regulation 8 (as amended regulation 6 regulation 2007) principal regulation amended-- (a) paragraph (2)(b) substituting 10 day 5 day (b) inserting paragraph (3) following paragraph circumstance arising (4) notwithstanding provision paragraph (1)(d) (2)(c) covid-19 emergency authorised person supply controlled drug specified schedule 2 3 4 misuse drug accordance regulation 2017 otherwise prescription guilty offence opinion authorised person is-- (a) unreasonable time supply circumstance arising covid-19 emergency person obtain new prescription medicinal product (b) safe appropriate necessary continued treatment person emergency supply made greater quantity product provide 5 day treatment supplied (5) notwithstanding provision paragraph (1)(d) (2)(c) (4) circumstance arising covid-19 emergency condition specified paragraph (1)(d) (2)(c) shall apply product consists contains midazolam clobazam clonazepam (but substance specified fourth schedule schedule 1 2 3 4 misuse drug regulation 2017 amendment thereof) supplied treatment epilepsy", "start_char": 10426, "end_char": 11959, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-reg-6", "parent_doc_id": "si-2020-0098", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "6. Regulation 10 (as amended by Regulation 5 of the Regulations of 2015)", "text_raw": "6. Regulation 10 (as amended by Regulation 5 of the Regulations of 2015) \nof the Principal Regulations is amended by inserting after paragraph (6) the \nfollowing paragraphs: \n\n \n \n \n\f[98] 7 \n\n“(7) Notwithstanding paragraph (3)(b), in the case of a prescription \ntransmitted by the national electronic prescription transfer system, the \nperson dispensing the prescription shall— \n\n(a) print the prescription as transmitted and treat it as an original \n\nprescription for the purposes of record-keeping, and \n\n(b) preserve and keep available for inspection for a period of two \nyears from the relevant date that printed copy and the electronic \nversion of the prescription. \n\n(8) Notwithstanding paragraph (3)(b), in the case of a prescription \ndispensed in accordance with Regulation 7(2A) where the original \nprescription is not available, the person dispensing the prescription shall \npreserve and keep available for inspection for a period of two years \nfrom the date of supply the record referred to in Regulation 7(2A)(i).”. \n\nGIVEN under my Official Seal, \n\n2 April, 2020. \n\nSIMON HARRIS, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n\f8 [98]", "text_norm": "6 regulation 10 (as amended regulation 5 regulation 2015) principal regulation amended inserting paragraph (6) following paragraph 98 7 (7) notwithstanding paragraph (3)(b) case prescription transmitted national electronic prescription transfer system person dispensing prescription shall-- (a) print prescription transmitted treat original prescription purpose record-keeping (b) preserve keep available inspection period two year relevant date printed copy electronic version prescription (8) notwithstanding paragraph (3)(b) case prescription dispensed accordance regulation 7(2a) original prescription available person dispensing prescription shall preserve keep available inspection period two year date supply record referred regulation 7(2a)(i)  given official seal 2 april 2020 simon harris minister health 8 98", "start_char": 11959, "end_char": 13107, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
{"doc_id": "si-2020-0098-explanatory-note", "parent_doc_id": "si-2020-0098", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 98 of 2020", "title": "Regulations of 2007, Part 4 of the Medicinal Products (Control of Placing on", "year": 2020, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to introduce temporary measures to \naddress the Covid-19 emergency. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) Regulations 2020. \n\n \n \n \n \n \n \n \n\f[98] 9 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-57) 75. 04/20. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation introduce temporary measure address covid-19 emergency regulation may cited medicinal product (prescription control supply) (amendment) regulation 2020 98 9 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur 3.00 (dh-57) 75 04 20 propylon", "start_char": 13107, "end_char": 14033, "source_path": "downloads\\2020\\2020_0097.pdf", "extraction_method": "pdfminer", "checksum": "sha256:32f3c88f92bf92e1b0e96112f6395a79a0bfde2ca76e3a81564cd964b75c4521", "cross_refs": []}
